Table 1.

Summary of peptide selection

	HLA class I TUMAPs									HLA class II TUMAP
TUMAP selection criteria	IMA-ADF-001	IMA-ADF-002	IMA-APO-001	IMA-CCN-001	IMA-GUC-001	IMA-K67–001	IMA-MET-001	IMA-MUC-001	IMA-RGS-001	IMA-MMP-001
Natural TUMAP presentation on RCC samples
Natural presentation directly shown on RCC tumor samples	X	X	X	—	X	X	X	—	X	X
TUMAP binding to HLA
Demonstrated high-affinity binding to HLA-A*02	X	X	X	X	X	X	X	(X)	—
Predicted promiscuous binding to HLA-DR in >80% of patients1										X
Demonstrated promiscuous binding to class II alleles1										X
mRNA overexpression of TUMAP source protein
Over-expression in RCC samples (% of analyzed RCC samples)2	95	95	100	93	90	85	98	65	80	70
Immunogenicity of TUMAPs
In vitro immunogenicity demonstrated	X	X	X	X	X	X	X	X	X	X
Immunogenicity proven in clinical trials	X	X	X	X	X	X	X	X	X	X
Relevant cancer-associated functions of source proteins
roles in cell cycle progression and tumor cell proliferation				X		X				X
tumor invasion, cell migration, and metastasis					X		X			X
linked to cancer-associated signaling pathways				X	X		X			X
antiapoptotic effects										X
pro-angiogenic effects							X		X
renal cell carcinoma marker	X	X					X			X
expression associated with mutations in the VHL gene	X	X		X
expression correlated with higher tumor stage/grade				X				X	X	X
overexpression linked to decreased survival in RCC							X		X	X

¹Not applicable to short HLA class I TUMAPs.

²Number of samples with expression > mean expression by normal tissues.